AHCPR to Fund Analysis of the Impact of Managed Care's Growth

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 12
Volume 5
Issue 12

WASHINGTON--The Agency for Health Care Policy and Research (AHCPR) has funded a new analysis of the impact of the recent growth and concentration of HMOs on employers, health-insurance coverage decisions, health care premiums, and employees' health insurance choices. Jack Hadley, MD, of Georgetown University, will lead the $307,437, year-long project.

WASHINGTON--The Agency for Health Care Policy and Research (AHCPR)has funded a new analysis of the impact of the recent growth andconcentration of HMOs on employers, health-insurance coveragedecisions, health care premiums, and employees' health insurancechoices. Jack Hadley, MD, of Georgetown University, will leadthe $307,437, year-long project.

Related Videos
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
A panel of 4 experts on multiple myeloma seated at a long table
A panel of 4 experts on multiple myeloma seated at a long table
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
The difference in adverse effect profiles between sorafenib and nirogacestat may make one treatment more appealing than the other for certain patients with desmoid tumors, says Brian Van Tine, MD, PhD.
Related Content